480 related articles for article (PubMed ID: 32061923)
1. Dipeptidyl peptidase 4 inhibitors and their potential immune modulatory functions.
Shao S; Xu Q; Yu X; Pan R; Chen Y
Pharmacol Ther; 2020 May; 209():107503. PubMed ID: 32061923
[TBL] [Abstract][Full Text] [Related]
2. Cut to the chase: a review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune system.
Klemann C; Wagner L; Stephan M; von Hörsten S
Clin Exp Immunol; 2016 Jul; 185(1):1-21. PubMed ID: 26919392
[TBL] [Abstract][Full Text] [Related]
3. A novel multi-epitope vaccine based on Dipeptidyl Peptidase 4 prevents streptozotocin-induced diabetes by producing anti-DPP4 antibody and immunomodulatory effect in C57BL/6J mice.
Li Z; Fang J; Jiao R; Wei X; Ma Y; Liu X; Cheng P; Li T
Biomed Pharmacother; 2017 May; 89():1467-1475. PubMed ID: 28376584
[TBL] [Abstract][Full Text] [Related]
4. Immunomodulatory activity of dipeptidyl peptidase-4 inhibitors in immune-related diseases.
Drakul M; Čolić M
Eur J Immunol; 2023 Dec; 53(12):e2250302. PubMed ID: 37732495
[TBL] [Abstract][Full Text] [Related]
5. Dipeptidyl Peptidase 4 Inhibitors Reduce Hepatocellular Carcinoma by Activating Lymphocyte Chemotaxis in Mice.
Nishina S; Yamauchi A; Kawaguchi T; Kaku K; Goto M; Sasaki K; Hara Y; Tomiyama Y; Kuribayashi F; Torimura T; Hino K
Cell Mol Gastroenterol Hepatol; 2019; 7(1):115-134. PubMed ID: 30510994
[TBL] [Abstract][Full Text] [Related]
6. Dipeptidyl peptidase inhibitor therapy in type 2 diabetes: Control of the incretin axis and regulation of postprandial glucose and lipid metabolism.
Mulvihill EE
Peptides; 2018 Feb; 100():158-164. PubMed ID: 29412815
[TBL] [Abstract][Full Text] [Related]
7. An emerging role of dipeptidyl peptidase 4 (DPP4) beyond glucose control: potential implications in cardiovascular disease.
Zhong J; Rao X; Rajagopalan S
Atherosclerosis; 2013 Feb; 226(2):305-14. PubMed ID: 23083681
[TBL] [Abstract][Full Text] [Related]
8. Dipeptidyl peptidase-4 (CD26): knowing the function before inhibiting the enzyme.
Matteucci E; Giampietro O
Curr Med Chem; 2009; 16(23):2943-51. PubMed ID: 19689275
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic Perspectives of CD26 Inhibitors in Imune-Mediated Diseases.
Hu X; Wang X; Xue X
Molecules; 2022 Jul; 27(14):. PubMed ID: 35889373
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of neurodegeration in type 2 diabetes and the neuroprotective potential of dipeptidyl peptidase 4 inhibitors.
Matteucci E; Giampietro O
Curr Med Chem; 2015; 22(13):1573-81. PubMed ID: 25723507
[TBL] [Abstract][Full Text] [Related]
11. Identification of levomenthol derivatives as potential dipeptidyl peptidase-4 inhibitors: a comparative study with gliptins.
Alade AA; Ahmed SA; Mujwar S; Kikiowo B; Akinnusi PA; Olubode SO; Olufemi OM; Ohilebo AA
J Biomol Struct Dyn; 2024 May; 42(8):4029-4047. PubMed ID: 37261796
[TBL] [Abstract][Full Text] [Related]
12. Targeting cluster of differentiation 26 / dipeptidyl peptidase 4 (CD26/DPP4) in organ fibrosis.
Ohm B; Moneke I; Jungraithmayr W
Br J Pharmacol; 2023 Nov; 180(22):2846-2861. PubMed ID: 36196001
[TBL] [Abstract][Full Text] [Related]
13. Emerging roles of dipeptidyl peptidase 4 inhibitors: anti-inflammatory and immunomodulatory effect and its application in diabetes mellitus.
Yang L; Yuan J; Zhou Z
Can J Diabetes; 2014 Dec; 38(6):473-9. PubMed ID: 25034244
[TBL] [Abstract][Full Text] [Related]
14. The many facets of CD26/dipeptidyl peptidase 4 and its inhibitors in disorders of the CNS - a critical overview.
Bernstein HG; Keilhoff G; Dobrowolny H; Steiner J
Rev Neurosci; 2023 Jan; 34(1):1-24. PubMed ID: 35771831
[TBL] [Abstract][Full Text] [Related]
15. Dipeptidyl Peptidase 4: A New Link between Diabetes Mellitus and Atherosclerosis?
Silva Júnior WS; Godoy-Matos AF; Kraemer-Aguiar LG
Biomed Res Int; 2015; 2015():816164. PubMed ID: 26146634
[TBL] [Abstract][Full Text] [Related]
16. The new insights from DPP-4 inhibitors: their potential immune modulatory function in autoimmune diabetes.
Zhao Y; Yang L; Wang X; Zhou Z
Diabetes Metab Res Rev; 2014 Nov; 30(8):646-53. PubMed ID: 24446278
[TBL] [Abstract][Full Text] [Related]
17. CD26/DPP4 levels in peripheral blood and T cells in patients with type 2 diabetes mellitus.
Lee SA; Kim YR; Yang EJ; Kwon EJ; Kim SH; Kang SH; Park DB; Oh BC; Kim J; Heo ST; Koh G; Lee DH
J Clin Endocrinol Metab; 2013 Jun; 98(6):2553-61. PubMed ID: 23539735
[TBL] [Abstract][Full Text] [Related]
18. A Cross-Sectional Study Comparing the Prevalence of Bullous Pemphigoid Autoantibodies in 275 Cases of Type II Diabetes Mellitus Treated With or Without Dipeptidyl Peptidase-IV Inhibitors.
Izumi K; Nishie W; Beniko M; Shimizu H
Front Immunol; 2019; 10():1439. PubMed ID: 31297116
[No Abstract] [Full Text] [Related]
19. Dipeptidyl peptidase IV and its inhibitors: therapeutics for type 2 diabetes and what else?
Juillerat-Jeanneret L
J Med Chem; 2014 Mar; 57(6):2197-212. PubMed ID: 24099035
[TBL] [Abstract][Full Text] [Related]
20. Dipeptidyl peptidase-4 inhibitors: multitarget drugs, not only antidiabetes drugs.
Zhao Y; Yang L; Zhou Z
J Diabetes; 2014 Jan; 6(1):21-9. PubMed ID: 23683065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
